|
Indicator: 1
[Output]
Measurements in/of Recommendations Made
Relationships: Department of Health and Human Services - Narrower_Than
Other Information:
Sickle Cell Disease Advisory Committee
| Type |
Target |
Actual |
| StartDate |
2010-10-01 |
2010-10-01 |
| EndDate |
2011-09-30 |
2011-09-30 |
| Number |
n/a |
33 |
| Description |
Unspecified |
There were 11 recommendations produced by the Board during FY 11 included to build the infrastructure needed to provide an
adequate number of eligible patients to SCD research; develop or collect best practices, which can be used as a set of prerequisites
for future trials supported by NHLBI; exploit the wide knowledge base outside SCD by bringing in high-quality laboratories
from other fields; support more mechanistic studies and studies that explore new agents targeting upstream events in the pathophysiology
of SCD; reward innovation; support health services research; enhance collaborations with other Federal agencies, private funders,
the Sickle Cell Disease Association of America and population scientists to advance research on SCD and other hemoglobinopathies;
leverage the successes of the Comprehensive Sickle Cell Centers and the BTRP; basic and translational research on definitive
therapies should include hemoglobin switching agents, pain management, prevention and treatment of stroke, acute chest syndrome,
and other anti-sickling agents; distributed clinical trials infrastructure should include SCD Clinical Trials Network, leverage
CTSAs, R34 mechanism, and trials should favor translational emphasis including biomakers; basic and translational pathophysiology
research should include outreach to other Institutes and Agencies, and include areas such as CNS changes, coagulopathy and
vasculopathy, role of inflammation and immunity, and chest syndrome.
|
|
